Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard I Scher

Showing results (11-20 of 392) with videos related to

Pageof 40
Sort By:
JAMA Oncology|May 12, 2017
Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate CancerWassim Abida, Howard I Scher
Seminars in Urologic Oncology|May 16, 2002
Outcome predictions for patients with metastatic prostate cancerOren Smaletz, Howard I Scher
Nature Reviews. Clinical Oncology|January 11, 2012
Prostate cancer in 2011: Hitting old targets better and identifying new targetsYu Chen, Howard I Scher
The Lancet. Oncology|July 10, 2003
Prostate cancer: a dynamic illness with shifting targetsDavid R Shaffer, Howard I Scher
European Journal of Nuclear Medicine and Molecular Imaging|January 24, 2007
(11)C-acetate PET imaging in prostate cancerMichael J Morris, Howard I Scher
Surgical Oncology|May 29, 2002
Novel therapies for the treatment of prostate cancer: current clinical trials and development strategiesMichael J Morris, Howard I Scher
JAMA Oncology|May 15, 2025
Can Ultra-Hypofractionated Stereotactic Radiation After Radical Prostatectomy Cut Time on Treatment or Are the Data Not Sharp Enough?Sean M McBride, Howard I Scher
Urologic Oncology|January 27, 2015
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approvalGabriel P Haas, Howard I Scher
The Journal of Urology|November 21, 2002
Editorial: States and state transitions are all that really matterHoward I Scher, William K Kelly
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?Matthew D Galsky, Howard I Scher
Pageof 40

Showing results (11-20 of 392) with videos related to

Sort By:
Pageof 40
JAMA Oncology|May 12, 2017
Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate CancerWassim Abida, Howard I Scher
Seminars in Urologic Oncology|May 16, 2002
Outcome predictions for patients with metastatic prostate cancerOren Smaletz, Howard I Scher
Nature Reviews. Clinical Oncology|January 11, 2012
Prostate cancer in 2011: Hitting old targets better and identifying new targetsYu Chen, Howard I Scher
The Lancet. Oncology|July 10, 2003
Prostate cancer: a dynamic illness with shifting targetsDavid R Shaffer, Howard I Scher
European Journal of Nuclear Medicine and Molecular Imaging|January 24, 2007
(11)C-acetate PET imaging in prostate cancerMichael J Morris, Howard I Scher
Surgical Oncology|May 29, 2002
Novel therapies for the treatment of prostate cancer: current clinical trials and development strategiesMichael J Morris, Howard I Scher
JAMA Oncology|May 15, 2025
Can Ultra-Hypofractionated Stereotactic Radiation After Radical Prostatectomy Cut Time on Treatment or Are the Data Not Sharp Enough?Sean M McBride, Howard I Scher
Urologic Oncology|January 27, 2015
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approvalGabriel P Haas, Howard I Scher
The Journal of Urology|November 21, 2002
Editorial: States and state transitions are all that really matterHoward I Scher, William K Kelly
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?Matthew D Galsky, Howard I Scher
Pageof 40